How researchers can get a handle on the monkey shortage for tox studies: FDA explains
The FDA on Friday released a new guidance to help researchers deal with the Covid-related challenges of monkey shortages available for conducting nonclinical tox studies, which has been an ongoing issue with few signs of a resolution.
Each of the hundreds of Covid-focused drugs and vaccines looking to come to market must undergo tox studies, typically in monkeys, prior to human trials. But this shortage in monkeys for the research hasn’t just been an increase in demand, as the Atlantic explained. China cut off supplies during the pandemic, and there’s been a longstanding shortage, even prior to the pandemic.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.